UBS Group
PRAX icon

UBS Group’s Praxis Precision Medicines PRAX Stock Holding History

UBS Group’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-44,200
Closed -$1.86M – 10796
2025
Q2 		$1.86M Sell
44,200
-800
-2% -$30.5K ﹤0.01% 4896
2025
Q1 		$1.7M Buy
+45,000
New +$2.81M ﹤0.01% 4842

Other funds holding PRAX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

UBS Group's PRAX Position: Q1 2026 in Review

UBS Group increased its Praxis Precision Medicines (PRAX) stake by 22% in Q1 2026, buying an estimated $5.95M and bringing the position to 108,446 shares worth $34.9M. The position accounts for 0.01% of the portfolio, ranked #2002.

UBS Group first reported a position in PRAX in Q4 2020 and has held it in 18 quarters since. 289 funds tracked by Wall St. Rank hold PRAX as of Q1 2026.

  • UBS Group held 108,446 shares of Praxis Precision Medicines worth $34.9M as of Q1 2026.
  • UBS Group bought 19,246 Praxis Precision Medicines shares in Q1 2026, an estimated $5.95M.
  • Praxis Precision Medicines made up 0.01% of UBS Group's portfolio in Q1 2026, its #2002 holding.
  • UBS Group first reported a position in Praxis Precision Medicines in Q4 2020 and has held it in 18 quarters since.
  • 289 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.